X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-09-15 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $27.00 | -1,195 | 395,794 | 0% | -$32,265 | ||||||
2026-09-16 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Dir | P - Purchase | $100.00 | +5,000 | 1,069,046 | 0% | +$500,000 | ||||||
2026-09-16 | HALO | Halozyme Therapeutics, Inc. | Posard Matthew L. | Dir | S - Sale | $107.74 | -18,996 | 58,839 | -24% | -$2,046,581 | ||||||
| D | 2026-09-15 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $72.98 | -1,000 | 0 | -100% | -$72,980 | |||||
| D | 2026-09-15 | TARS | Tarsus Pharmaceuticals, Inc. | Link William J Phd | Dir | S - Sale+OE | $78.38 | -12,500 | 94,487 | -12% | -$979,744 | |||||
2026-09-16 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.21 | +11,000 | 102,822 | +12% | +$2,310 | ||||||
| M | 2026-09-14 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.57 | +123,918 | 3,272,141 | +4% | +$1,062,506 | |||||
2026-09-14 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $13.90 | -58,333 | 767,486 | -7% | -$811,004 | ||||||
| DM | 2026-09-14 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $145.10 | -80,575 | 1,718,078 | -4% | -$11,691,420 | |||||
| M | 2026-09-15 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $96.37 | -49,000 | 39,771,320 | 0% | -$4,721,976 | |||||
2026-09-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $145.29 | -3,000 | 164,096 | -2% | -$435,870 | ||||||
2026-09-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale | $144.22 | -3,000 | 116,684 | -3% | -$432,646 | ||||||
2026-09-15 | DNA | Ginkgo Bioworks Holdings, Inc. | Henry Christian O | Dir | S - Sale | $7.08 | -5,000 | 19,310 | -21% | -$35,405 | ||||||
| D | 2026-09-15 | FENC | Fennec Pharmaceuticals Inc. | Brughera Marco Maria | Dir | S - Sale+OE | $10.29 | -15,545 | 0 | -100% | -$159,958 | |||||
2026-09-15 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.22 | +22,000 | 91,822 | +32% | +$4,862 | ||||||
2026-09-14 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $1.93 | -2,587 | 601,971 | 0% | -$4,993 | ||||||
2026-09-14 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $1.93 | -1,658 | 502,907 | 0% | -$3,200 | ||||||
| D | 2026-09-11 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $202.36 | -92,531 | 291,876 | -24% | -$18,724,767 | |||||
| M | 2026-09-11 | INBX | Inhibrx Biosciences, Inc. | Manhard Kimberly | Dir | S - Sale | $109.03 | -1,500 | 7,500 | -17% | -$163,543 | |||||
2026-09-14 | NBIX | Neurocrine Biosciences Inc | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $157.45 | -826 | 8,722 | -9% | -$130,051 | ||||||
2026-09-14 | NBIX | Neurocrine Biosciences Inc | Abernethy Matt | CFO | S - Sale | $157.20 | -2,311 | 42,808 | -5% | -$363,285 | ||||||
2026-09-14 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.22 | +5,900 | 69,822 | +9% | +$1,292 | ||||||
2026-09-14 | HUMA | Humacyte, Inc. | Jones Keith Anthony | Dir | P - Purchase | $0.56 | +10,000 | 50,000 | +25% | +$5,620 | ||||||
| D | 2026-09-10 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $204.16 | -15,448 | 43,890 | -26% | -$3,153,807 | |||||
| D | 2026-09-10 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $134.49 | -34,836 | 59,375 | -37% | -$4,685,094 | |||||
2026-09-09 | OCGN | Ocugen, Inc. | Musunuri Shankar | CEO | S - Sale | $1.12 | -525,991 | 5,575,232 | -9% | -$589,110 | ||||||
| DM | 2026-09-09 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $107.28 | -60,000 | 767,780 | -7% | -$6,436,711 | |||||
2026-09-09 | MGX | Metagenomi Therapeutics, Inc. | Reid Laurence | Dir | P - Purchase | $1.17 | +20,000 | 20,000 | New | +$23,401 | ||||||
| DM | 2026-09-10 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO | S - Sale+OE | $11.28 | -280,245 | 113,321 | -71% | -$3,160,783 | |||||
2026-09-10 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $96.31 | -20,500 | 39,906,320 | 0% | -$1,974,287 | ||||||
| D | 2026-09-09 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $154.61 | -2,154 | 64,408 | -3% | -$333,030 | |||||
| M | 2026-09-08 | INBX | Inhibrx Biosciences, Inc. | Manhard Kimberly | Dir | S - Sale | $115.47 | -1,000 | 9,000 | -10% | -$115,468 | |||||
2026-09-08 | RXRX | Recursion Pharmaceuticals, Inc. | Khan Najat | CEO, Pres | S - Sale | $3.52 | -22,408 | 2,072,890 | -1% | -$78,822 | ||||||
2026-09-08 | RVMD | Revolution Medicines, Inc. | Kim Lorence H. | Dir | S - Sale | $209.82 | -17,090 | 1,191 | -93% | -$3,585,837 | ||||||
2026-09-08 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $122.62 | -412 | 73,651 | -1% | -$50,521 | ||||||
2026-09-08 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $122.62 | -907 | 117,014 | -1% | -$111,220 | ||||||
| D | 2026-09-08 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $122.62 | -2,302 | 768,427 | 0% | -$282,280 | |||||
2026-09-08 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $122.62 | -238 | 44,399 | -1% | -$29,185 | ||||||
2026-09-08 | MGX | Metagenomi Therapeutics, Inc. | Wein Matthew | See Remarks | S - Sale | $1.16 | -358 | 126,133 | 0% | -$415 | ||||||
2026-09-08 | MGX | Metagenomi Therapeutics, Inc. | Irish Jian | See Remarks | S - Sale | $1.16 | -2,140 | 960,820 | 0% | -$2,479 | ||||||
2026-09-08 | MGX | Metagenomi Therapeutics, Inc. | Wapnick Pamela | CFO | S - Sale | $1.16 | -1,911 | 206,580 | -1% | -$2,214 | ||||||
| D | 2026-09-08 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale+OE | $21.57 | -8,000 | 158,844 | -5% | -$172,560 | |||||
| M | 2026-09-04 | PCVX | Vaxcyte, Inc. | Wassil Jim | EVP, Chief Scientific Ofc, COO | S - Sale | $60.35 | -2,715 | 145,435 | -2% | -$163,863 | |||||
| M | 2026-09-08 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $98.50 | -73,000 | 39,926,820 | 0% | -$7,190,663 | |||||
2026-09-04 | DNLI | Denali Therapeutics Inc. | Chin Peter Scott | Chief Medical Officer | S - Sale | $22.29 | -1,654 | 204,538 | -1% | -$36,868 | ||||||
2026-09-08 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $2.05 | -534 | 604,558 | 0% | -$1,095 | ||||||
2026-09-08 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $2.05 | -254 | 504,565 | 0% | -$521 | ||||||
2026-09-08 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $18.97 | -8,530 | 399,130 | -2% | -$161,814 | ||||||
2026-09-08 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $18.94 | -17,717 | 122,851 | -13% | -$335,560 | ||||||
2026-09-04 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $90.56 | -10,000 | 861,412 | -1% | -$905,600 | ||||||
2026-09-04 | TARS | Tarsus Pharmaceuticals, Inc. | Lin Elizabeth Yeu | Chief Medical Officer | S - Sale | $87.50 | -13,953 | 16,177 | -46% | -$1,220,885 | ||||||
2026-09-04 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $85.00 | -4,564 | 79,007 | -5% | -$387,940 | ||||||
2026-09-08 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $18.94 | -48,199 | 1,406,403 | -3% | -$912,889 | ||||||
2026-09-08 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $10.92 | -23,429 | 1,449,765 | -2% | -$255,746 | ||||||
2026-09-08 | INBX | Inhibrx Biosciences, Inc. | Kayyem Jon Faiz | Dir | P - Purchase | $113.52 | +5,000 | 1,064,046 | 0% | +$567,580 | ||||||
2026-09-03 | EIKN | Eikon Therapeutics, Inc. | Column Group IV Gp, LP | 10% | P - Purchase | $11.56 | +89,200 | 5,869,343 | +2% | +$1,031,045 | ||||||
2026-09-08 | INBX | Inhibrx Biosciences, Inc. | Forsyth Douglas | Dir | P - Purchase | $114.65 | +2,500 | 227,064 | +1% | +$286,617 | ||||||
2026-09-04 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale | $26.22 | -9,705 | 0 | -100% | -$254,502 | ||||||
2026-09-04 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale | $165.90 | -3,035 | 48,369 | -6% | -$503,507 | ||||||
| M | 2026-09-03 | BNTX | Biontech Se | Sahin Ugur | CEO, 10% | S - Sale | $103.13 | -76,500 | 781,709 | -9% | -$7,889,055 | |||||
2026-09-08 | INBX | Inhibrx Biosciences, Inc. | Lappe Mark | CEO | P - Purchase | $105.82 | +25,000 | 950,413 | +3% | +$2,645,399 | ||||||
2026-09-03 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.09 | +800 | 381,985 | 0% | +$872 | ||||||
2026-09-04 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $359.32 | -25,000 | 1,493,155 | -2% | -$8,982,986 | ||||||
2026-09-04 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $359.32 | -25,000 | 1,565,253 | -2% | -$8,983,084 | ||||||
2026-09-04 | ATRA | Atara Biotherapeutics, Inc. | Cherry Brian N | Dir | P - Purchase | $9.60 | +104,166 | 166,486 | +167% | +$999,994 | ||||||
2026-09-04 | KYMR | Kymera Therapeutics, Inc. | Adams Brian | GC | S - Sale | $116.83 | -6,371 | 50,254 | -11% | -$744,297 | ||||||
| M | 2026-09-02 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $2.61 | -9,446 | 106,015 | -8% | -$24,666 | |||||
2026-09-03 | ALEC | Alector, Inc. | Berkley Neil Lindsay | CFO, Chief Business Officer | S - Sale | $2.66 | -29,251 | 350,649 | -8% | -$77,948 | ||||||
2026-09-03 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $2.66 | -72,606 | 6,224,975 | -1% | -$193,473 | ||||||
2026-09-02 | DNLI | Denali Therapeutics Inc. | Thornberry Nancy | Dir | S - Sale | $22.90 | -11,439 | 19,686 | -37% | -$261,929 | ||||||
2026-09-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $3.04 | -709 | 61,660 | -1% | -$2,153 | ||||||
| M | 2026-09-02 | MAZE | Maze Therapeutics, Inc. | Courtney Phillips | GC, Corp. Secretary | S - Sale | $26.24 | -3,993 | 7,007 | -36% | -$104,766 | |||||
| M | 2026-09-02 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale | $26.24 | -6,434 | 32,316 | -17% | -$168,811 | |||||
2026-09-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $3.04 | -453 | 13,839 | -3% | -$1,376 | ||||||
| M | 2026-09-02 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.24 | -22,638 | 268,868 | -8% | -$593,955 | |||||
2026-09-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $3.04 | -5,124 | 243,189 | -2% | -$15,563 | ||||||
| M | 2026-09-02 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale | $26.24 | -10,295 | 9,705 | -51% | -$270,111 | |||||
2026-09-03 | ARTV | Artiva Biotherapeutics, Inc. | Horan Christopher | Chief Tech Operations Officer | S - Sale | $11.16 | -10,366 | 283,084 | -4% | -$115,638 | ||||||
2026-09-03 | ARTV | Artiva Biotherapeutics, Inc. | Bush Jennifer | COO, CLO, Compliance Officer | S - Sale | $11.16 | -8,391 | 329,529 | -2% | -$93,606 | ||||||
2026-09-03 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale | $11.16 | -1,100 | 140,947 | -1% | -$12,271 | ||||||
2026-09-03 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $11.16 | -61,888 | 1,473,194 | -4% | -$690,392 | ||||||
| D | 2026-09-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $14.00 | -584 | 8,617 | -6% | -$8,176 | |||||
| D | 2026-09-01 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $139.95 | -3,471 | 75,247 | -4% | -$485,766 | |||||
2026-09-02 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $80.06 | -10,000 | 871,412 | -1% | -$800,600 | ||||||
| D | 2026-09-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $61.07 | -3,477 | 153,609 | -2% | -$212,352 | |||||
| M | 2026-08-26 | EXOZ | Exozymes Inc. | Heltzen Michael | CEO | P - Purchase | $7.49 | +855 | 13,853 | +7% | +$6,405 | |||||
2026-09-01 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.34 | -30,000 | 6,158,287 | 0% | -$100,200 | ||||||
2026-08-31 | RVMD | Revolution Medicines, Inc. | Kim Lorence H. | Dir | S - Sale | $203.24 | -56,000 | 18,281 | -75% | -$11,381,288 | ||||||
2026-09-01 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $148.64 | -15,000 | 577,133 | -3% | -$2,229,592 | ||||||
2026-09-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Former Director | S - Sale | $12.11 | -10,000 | 124,411 | -7% | -$121,100 | ||||||
2026-08-31 | VIVS | Vivosim Labs, Inc. | Lialin Tony Serge | Chief Commercial Officer | P - Purchase | $0.28 | +10,000 | 10,000 | New | +$2,804 | ||||||
2026-08-31 | FENC | Fennec Pharmaceuticals Inc. | Sayad Pierre Sargis | Chief Medical Officer | S - Sale | $12.18 | -12,000 | 9,519 | -56% | -$146,160 | ||||||
| D | 2026-08-27 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale+OE | $12.01 | -8,222 | 142,047 | -5% | -$98,736 | |||||
| D | 2026-08-28 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $27.58 | -7,500 | 26,250 | -22% | -$206,824 | |||||
2026-08-26 | ADPT | Adaptive Biotechnologies Corp | Owen Katey Einterz | Dir | S - Sale | $26.00 | -9,615 | 78,639 | -11% | -$249,990 | ||||||
| D | 2026-08-27 | FENC | Fennec Pharmaceuticals Inc. | Andrade Robert | CFO | S - Sale+OE | $11.78 | -75,000 | 239,603 | -24% | -$883,500 | |||||
| ADM | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | Walsh Colin | Dir | P - Purchase | $17.58 | +585,000 | 3,020,632 | +24% | +$10,285,000 | |||||
| AD | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | Walsh Colin | Dir | S - Sale+OE | $21.28 | -105,807 | 3,020,632 | -3% | -$2,251,658 | |||||
2026-08-26 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $20.03 | -4,508 | 223,657 | -2% | -$90,295 | ||||||
| D | 2026-08-28 | IMVT | Immunovant, Inc. | Pande Atul | Dir | S - Sale+OE | $43.27 | -1,500 | 136,731 | -1% | -$64,905 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |